47 signals · bluesky, News / RSS
Scores are directional signals derived from aggregated public data — not verified findings or investment advice. Methodology
Signal-based estimates from public data — not verified assessments. Learn more
Moderate stress signals detected across available public data.
Low-to-moderate risk signals with no major red flags in current data.
Signal data from 1 source places Roche in the Pharmaceuticals / Diagnostics space at moderate workforce stress signals with low overall risk indicators.
Signals for Roche were collected from 1 source. Aggregate signal sentiment appears mixed or neutral. The stress score stands at 46/100 with a risk score of 26/100. Signal coverage is sufficient to support a preliminary assessment.
Roundup: Orbis Enters $1.4 Billion Partnership with Novo, Dualitas Therapeutics Enters Research collaboration with Roche, Aethlon Medical Merges with North Immunology pharmexec.com
Dualitas Partners With Roche on Bispecific Antibody Discovery BioPharm International
Pharmaceutical and diagnostics company.
Based on 47 signals across 2 sources · snapshot 18 Sept 2026
Strong — enough signals from diverse sources to trust this score.
Overall community sentiment for Roche is mixed based on public signals as of 18 Sept 2026.
Based on 47 signals across 2 sources
Scores are directional signals derived from public data — not certified assessments or recommendations. Confidence indicates data coverage, not accuracy. Learn how scores are calculated →
Derived from public sources such as news, filings, and reported events.
What this means
Signals suggest a mixed picture — review the evidence below for context.
AI-generated from public signals — may be incomplete. Based on 3 recent signals.
This summary is generated from publicly available review and signal data. It is intended as an indicative overview only and should not be used as the sole basis for employment, investment, or business decisions. Signal volume and source diversity may limit representativeness.
AI summaries are generated from public signals and may not reflect the full picture.
Dualitas partners with Roche in up to $1 billion bispecific antibody deal The Pharma Letter